Literature DB >> 26622747

Cerebral tumefactive demyelinating lesions.

Wei Qi1, G E Jia1, Xinsheng Wang1, Maozhi Zhang1, Zhenyu Ma1.   

Abstract

Tumefactive demyelinating lesions (TDLs), are a rare demyelinating pathological disease in the central neurological system, which have been proven to be a diagnostic dilemma to neurosurgeons. The clinical presentation and radiographic appearance of these lesions often results in their misdiagnosis as intracranial tumors, such as gliomas, which leads to unnecessary surgical resection and adjunct radiation. In the present study, the clinical and radiographic features of 14 patients with cerebral TDLs who underwent surgical treatment between January 2004 and January 2009 were reviewed and analyzed. The surgical methods used included biopsy and resection, while steroid therapy was indicated when TDLs were confirmed by histopathological analysis. The patients were followed-up and the outcomes were evaluated using the Karnofsky performance scale (KPS). The main clinical presentations included: Hemiplegia (8 cases), increased intracranial pressure (4 cases) and seizures (general in 1 case; partial in 3 cases). On magnetic resonance imaging scans, 12/14 TDL cases demonstrated an isolated local subcortical mass and 6/14 cases (42.9%) demonstrated enhancing veins coursing undistorted through the lesion. The postoperative complications included: Hemiplegia (2 cases) and mortality (1 case). A total of 9 cases underwent microsurgical total resection, and 5 cases received stereotactic biopsy that was followed with high-dose methylprednisolone therapy. The follow-up study demonstrated that 2 cases presented recurrence with multiple sclerosis and the KPS scores for 13/14 patients (92.9%) were ≥80. In conclusion, the clinical and radiographic features of TDLs may help to establish the correct diagnosis prior to surgery, in order to avoid unnecessary resection or adjunctive therapy. Using steroid therapy, the majority of patients with TDLs appeared to achieve satisfactory prognosis.

Entities:  

Keywords:  clinical features; steroid therapy; tumefactive demyelinating lesions

Year:  2015        PMID: 26622747      PMCID: PMC4533738          DOI: 10.3892/ol.2015.3481

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  26 in total

1.  Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis.

Authors: 
Journal:  Am J Ophthalmol       Date:  2001-10       Impact factor: 5.258

Review 2.  Differential diagnosis of multiple sclerosis: contribution of magnetic resonance techniques.

Authors:  F Triulzi; G Scotti
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-05       Impact factor: 10.154

Review 3.  Therapeutic plasma exchange for acute inflammatory demyelinating syndromes of the central nervous system.

Authors:  B G Weinshenker
Journal:  J Clin Apher       Date:  1999       Impact factor: 2.821

4.  Plasma exchange for severe attacks of CNS demyelination: predictors of response.

Authors:  M Keegan; A A Pineda; R L McClelland; C H Darby; M Rodriguez; B G Weinshenker
Journal:  Neurology       Date:  2002-01-08       Impact factor: 9.910

Review 5.  Natural history of multiple sclerosis: implications for counselling and therapy.

Authors:  Christian Confavreux; Sandra Vukusic
Journal:  Curr Opin Neurol       Date:  2002-06       Impact factor: 5.710

6.  Late-onset multiple sclerosis mimicking brain tumor: a case report.

Authors:  Kazuhisa Iwamoto; Hidehiro Oka; Satoshi Utsuki; Tatsuya Ozawa; Kiyotaka Fujii
Journal:  Brain Tumor Pathol       Date:  2004       Impact factor: 3.298

7.  Spinal cord ring enhancement in multiple sclerosis.

Authors:  Eric C Klawiter; Tammie Benzinger; Abhik Roy; Robert T Naismith; Becky Jo Parks; Anne H Cross
Journal:  Arch Neurol       Date:  2010-11

8.  Multiple sclerosis mimicking primary brain tumor.

Authors:  S B Hunter; W E Ballinger; J J Rubin
Journal:  Arch Pathol Lab Med       Date:  1987-05       Impact factor: 5.534

9.  Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis.

Authors:  C F Lucchinetti; R H Gavrilova; I Metz; J E Parisi; B W Scheithauer; S Weigand; K Thomsen; J Mandrekar; A Altintas; B J Erickson; F König; C Giannini; H Lassmann; L Linbo; S J Pittock; W Brück
Journal:  Brain       Date:  2008-06-05       Impact factor: 13.501

10.  Distinct supratentorial lesions mimicking cerebral gliomas.

Authors:  G Wurm; B Parsaei; R Silye; F A Fellner
Journal:  Acta Neurochir (Wien)       Date:  2003-12-09       Impact factor: 2.216

View more
  6 in total

Review 1.  Differential imaging of atypical demyelinating lesions of the central nervous system.

Authors:  Matteo Paoletti; Shaun Ivan Muzic; Francesca Marchetti; Lisa Maria Farina; Stefano Bastianello; Anna Pichiecchio
Journal:  Radiol Med       Date:  2021-01-24       Impact factor: 3.469

Review 2.  Pattern Recognition of the Multiple Sclerosis Syndrome.

Authors:  Rana K Zabad; Renee Stewart; Kathleen M Healey
Journal:  Brain Sci       Date:  2017-10-24

3.  When tumefactive demyelination is truly a tumor: case report of a radiographic misdiagnosis.

Authors:  Breanna Taylor; Mallika P Patel; Katherine B Peters
Journal:  CNS Oncol       Date:  2021-01-15

Review 4.  A challenging diagnosis of late-onset tumefactive multiple sclerosis associated to cervicodorsal syringomyelia: doubtful CT, MRI, and bioptic findings: Case report and literature review.

Authors:  Renata Conforti; Raffaella Capasso; Rosario Galasso; Mario Cirillo; Gemma Taglialatela; Luigi Galasso
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

5.  Progression of tumefactive demyelinating lesion in a child demonstrated with MRI.

Authors:  Marta De Simone; Barbara Brogna; Daniele Litterio Spitaleri; Giulio Cicarelli; Roberta Fantozzi; Bruno Guida
Journal:  Radiol Case Rep       Date:  2017-12-08

Review 6.  Molecular imaging of multiple sclerosis: from the clinical demand to novel radiotracers.

Authors:  Matteo Bauckneht; Selene Capitanio; Stefano Raffa; Luca Roccatagliata; Matteo Pardini; Caterina Lapucci; Cecilia Marini; Gianmario Sambuceti; Matilde Inglese; Paolo Gallo; Diego Cecchin; Flavio Nobili; Silvia Morbelli
Journal:  EJNMMI Radiopharm Chem       Date:  2019-04-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.